Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Thursday 13th June, SOE 2019 – Rapid Fire: Top 9 Corneal Topics You Must Know!

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 12th 2019

Highlights from the Corneal Society session ‘Rapid Fire: Top 9 Corneal Topics You Must Know!’ presented at SOE 2019 featuring:

– New Drugs and Gadgets for Dry Eyes: Do they Work? Stephen Kaufmann (0:42)

– The Nerve of You: New Ways to Treat Neurotrophic Keratitis (NGF and Neutorization) Kathryn Colby (10:47)

– Does Suppressive Antiviral Treatment Prevent Recurrences of Herpes Zoster of the Anterior Segment? Bennie Jeng (21:24)

– Diagnostic Testing for LSCD: Is it Necessary? Sophie Deng (30:46)

– Cross Linking and Scleral Contact Lenses: The End of Keratoplasty for Keratokonus? Michael Belin (41:35)

Interface Keratitis after Lamellar Keratoplasty: How to Prevent and treat, Luigi Fontana (51:50)

– Prestripped, and Now Preloaded DMEK: Is This the Way of the Future? Barry Lee (1:02:20)

– DSAEK, DMEK, DSO: What am I Supposed to Do? Jennifer Rose-Nussabumer (1:13:33)

– Cell Injection and ROCK Inhibitors: No More Keratoplasty for Endothelial Dysfunction? Jod Mehta (1:22:55)

Filmed in partnership with the European Society of Ophthalmology (SOE) at the SOE 2019 meeting in Nice, France.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup